CA 19-9 Test Cost and Medicare Coverage (CPT 86301)

Also called: cancer antigen 19-9 · carbohydrate antigen 19-9 · CA 19-9 blood test · CA 19-9 level — all the same test, CPT 86301.

The short answer

Covered for one thing: following the course of a pancreatic or bile duct cancer that has already been diagnosed. Medicare’s national policy (NCD 190.30, the same in every state) says CA 19-9 levels “are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma,” and then closes the door on every other use in the next sentence: “The test is not indicated for diagnosing these two diseases.”

This is the tightest rule of the tumor marker policies. Diagnostic use is excluded twice, once in the indications and once in the limitations, which add: “These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy.” There is no frequency limit and no screening language, because there is nothing to limit: without an established diagnosis, there is no covered indication at all.

The sources agree that it is not a screening test. Cleveland Clinic’s page on the test is titled “Is the CA 19-9 Blood Test a Cancer Screening Test?” and answers: “No, it’s not.” Quest’s directory says “CA 19-9 should not be used as a screening test,” and Labcorp’s says “the determination of CA 19-9 cannot be used for the early detection of pancreatic carcinoma.”

When Medicare DOES cover it

The national policy’s covered picture, in plain English:

• Following an established pancreatic cancer. The policy’s word is “established”: the diagnosis has already been made by other means, and CA 19-9 is used to follow its course.
• Following an established bile duct cancer (“biliary ductal carcinoma”), on the same terms.
• Checking for recurrence, or response to treatment. The policy says the test “may be ordered at times necessary to assess either the presence of recurrent disease or the patient’s response to treatment with subsequent treatment cycles,” and its description says tumor markers like this one are for “monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.”

If one of these genuinely describes your situation, the diagnosis for it belongs on your doctor’s order, and coverage follows.

When Medicare does NOT cover it

• Diagnosing pancreatic or bile duct cancer. “The test is not indicated for diagnosing these two diseases.” A CA 19-9 drawn to find out whether someone has one of these cancers has no covered indication under this policy.
• Evaluating symptoms. “These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy.”
• Screening. The policy never uses the word, and it lists no covered use for anyone without an established diagnosis. Cleveland Clinic explains the difference: “Screening tests are routine tests, like a mammogram or PSA test, that you may have as part of your annual physical checkup,” and CA 19-9 is not one.
• Other cancers. The National Cancer Institute lists CA 19-9 as a marker for “pancreatic, gallbladder, bile duct, and gastric cancers,” but Medicare’s policy names only pancreatic and biliary ductal carcinoma. It says nothing about gastric or any other cancer, which means there is no covered indication in the policy for them.

(Never ask anyone to change a code just to get coverage; that is fraud. But doctors often have a legitimate reason for the test that simply wasn’t written down.)

What you pay if it IS covered: $0

Covered lab tests cost Medicare patients nothing, with no deductible and no 20% coinsurance. Medicare pays the lab $20.81 for a CA 19-9 test, and you owe zero.

What you pay if it is NOT covered, read this before you sign

Quest’s own test directory flags CA 19-9 as “subject to a Medicare Limited Coverage Policy” that “may require a signed ABN when ordering.” (Labcorp’s page carries no such notice.) If CA 19-9 is on your order without an established pancreatic or bile duct cancer diagnosis behind it, expect the Advance Beneficiary Notice (ABN), the signature pad, committing you to the lab’s own billing rates if Medicare denies the claim. Before you sign:

1. Ask the lab to print exactly what you would owe. You’re entitled to see the number in black and white first. For perspective: when Medicare covers this exact test, it pays the lab $20.81.
2. Know the direct prices: a CA 19-9 test sells for about $58.90 all in at Ulta Lab Tests (partner link in the table; our commission is disclosed there) and $53.00 all in at Jason Health (jasonhealth.com, including their flat $18 lab-collection fee per order). Quest’s consumer site, Labcorp OnDemand, and Personalabs do not sell it. Same certified labs, same blood draw.

Before you sign the pad, 60-second checklist

1. Ask: “Can you print what I’ll owe if Medicare doesn’t pay?”
2. Ask your doctor: “Is this to follow a cancer that is already diagnosed and on my chart, and is that diagnosis on the order?”
3. Compare the printed price to the direct-purchase prices before deciding how to proceed.

What counts as a “normal” CA 19-9 level

Start with the range printed on your own report. Only one of the sources we checked publishes a number for CA 19-9.

• Labcorp’s reference interval is 0 to 35 units/mL.
• Cleveland Clinic gives no number. It says only that “there’s a normal range for the lab result” and that “levels higher than that range may be a sign of certain cancers.”
• MedlinePlus gives no range, and Quest’s directory hides its range until a service area is chosen.

None of the sources we checked gives a treatment target for CA 19-9, so there is no “clinical target” to add here. Two cautions matter more than the number. The National Cancer Institute says “having an elevated level of a tumor marker does not mean that someone has cancer” and that “noncancerous conditions can sometimes cause an increase in the level of a tumor marker”; MedlinePlus says that “because high levels of CA 19-9 can mean different things, health care providers don’t use the results from a CA 19-9 test alone to screen for or diagnose cancer.” In the other direction, a normal result does not rule cancer out, and for CA 19-9 there is a specific reason: MedlinePlus says “some people do not make CA 19-9 even when they have a cancer that usually produces high levels of CA 19-9.” Labcorp puts a number on it: “three percent to 7% of the population have the Lewis a-negative/b-negative blood group configuration” and cannot make CA 19-9 at all. Cleveland Clinic’s figure is broader: “5 to 10 out of 100 people in the world have no CA 19-9 or low levels of the tumor marker.”

(Where lab ranges and “optimal” ranges come from, and who decides.)

This page can tell you where those numbers came from. It cannot tell you what yours means; that reading belongs to your doctor, alongside your imaging, your earlier levels, and your history.

Quick questions people ask

What is a CA 19-9 test? MedlinePlus says “a CA 19-9 test measures the amount of a protein called CA 19-9 (cancer antigen 19-9) in a sample of your blood.” Labcorp calls it carbohydrate antigen 19-9. The National Cancer Institute lists it as a marker for “pancreatic, gallbladder, bile duct, and gastric cancers.” On billing paperwork it is CPT code 86301.

Is CA 19-9 a screening test for pancreatic cancer? No. That is the title question of Cleveland Clinic’s page, and its answer is “No, it’s not.” Quest’s directory says “CA 19-9 should not be used as a screening test,” Labcorp’s says it “cannot be used for the early detection of pancreatic carcinoma,” and NCI says studies of tumor markers as screening tests “have generally found that these markers do not work well for screening.” Medicare’s policy says the test “is not indicated for diagnosing” pancreatic or bile duct cancer, and covers it only after a diagnosis is established.

Does a high CA 19-9 mean cancer? Not by itself. NCI says an elevated tumor marker “does not mean that someone has cancer” and that “noncancerous conditions can sometimes cause an increase in the level of a tumor marker.” NCI says marker results “are usually combined with the results of other tests, such as biopsies or imaging, to diagnose cancer.” What your result means is a conversation with your doctor.

Why might a CA 19-9 be normal even with cancer? Because some people cannot make it. Labcorp says “three percent to 7% of the population have the Lewis a-negative/b-negative blood group configuration” and cannot express CA 19-9; Cleveland Clinic says “5 to 10 out of 100 people in the world have no CA 19-9 or low levels of the tumor marker.” MedlinePlus puts it simply: “some people do not make CA 19-9 even when they have a cancer that usually produces high levels of CA 19-9.”

Do you have to fast for a CA 19-9 test? MedlinePlus says “usually, you don’t need any special preparations for a CA 19-9 blood test. But ask your provider to be sure.” Cleveland Clinic says “you don’t need to do anything to get ready for it,” and Quest’s directory lists no patient preparation.

Sources and data dates

Medicare payment amount: CMS Clinical Laboratory Fee Schedule, 2026 Q3 file (national rate for 86301). Coverage rules: CMS Medicare Coverage Database, NCD 190.30 (CA 19-9), a national policy identical in every state, and the same text in the NCD Manual, Chapter 1, Part 3. Test descriptions, preparation, and ranges: National Cancer Institute (Tumor Markers fact sheet and list), MedlinePlus (CA 19-9 Blood Test; Tumor Marker Tests), Cleveland Clinic (Is the CA 19-9 Blood Test a Cancer Screening Test?), Quest test 4698, Labcorp test 002261. Consumer prices checked September 2026. Information current as of the date shown above; coverage is always determined by Medicare when your claim is processed.

ClaraCover provides information, not medical, billing, or insurance advice. Talk to your doctor about what tests you need.